Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

BACKGROUND: This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: In Phase 2b, tepotinib was orally administered once daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryoo, Baek-Yeol, Cheng, Ann-Li, Ren, Zhenggang, Kim, Tae-You, Pan, Hongming, Rau, Kun-Ming, Choi, Hye Jin, Park, Joong-Won, Kim, Jee Hyun, Yen, Chia Jui, Lim, Ho Yeong, Zhou, Dongli, Straub, Josef, Scheele, Juergen, Berghoff, Karin, Qin, Shukui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292411/
https://www.ncbi.nlm.nih.gov/pubmed/33972742
http://dx.doi.org/10.1038/s41416-021-01380-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292411/
https://www.ncbi.nlm.nih.gov/pubmed/33972742
http://dx.doi.org/10.1038/s41416-021-01380-3

Ejemplares similares